In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.
Magazine
Kenneth Thorpe, from Emery University in Atlanta, and his colleagues found in a study carried out in the USA, that while the overall number of bacterial infections remained relatively constant between 2002 and 2014, rising from 13.5 million to 14.3 million annually, the proportion that were antibiotic-resistant rose dramatically, from 5.2% to 11.0%. Patients with antibiotic-resistant infections had spending for bacterial infection that was 165 percent higher than spending by patients without such infections. Sixty-one percent of antibiotic-resistant infections were associated with urinary tract infections. Their conclusion is that the direct costs and the mortality and morbidity attributable to antibiotic-resistant infections make a compelling case for urgent action by national and international policy makers.
We are pleased to announce the launch in France of UTIPRO® PLUS, our product for uncomplicated Urinary Tract Infections. The product is commercialized over the French territory under the umbrella brand Cysticare / Utipro plus and is distributed by Vemedia, our partner for the product in the Netherlands as well.
We are pleased to announce the launch in Israel of UTIPRO® PLUS, our product for uncomplicated Urinary Tract Infections. The product is distributed by our long term partner Lapidot.
Utipro® Plus is a medical device intended for the control and prevention of urinary tract infections produced by pathogens such as E.coli and other gram (-) bacteria normally involved in the etiology of urological infections.
Utipro® Plus has been presented to HCP and available as capsules for oral administration in pharmacies all across the Israeli territory since Q4 2017.
Utipro® Plus is a class III medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments. (CE 0373, Noventure SL)
